Compare BBCP & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | CADL |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.0M | 320.6M |
| IPO Year | 2017 | 2021 |
| Metric | BBCP | CADL |
|---|---|---|
| Price | $6.43 | $5.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.50 | ★ $19.43 |
| AVG Volume (30 Days) | 139.3K | ★ 738.2K |
| Earning Date | 03-10-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $392,867,000.00 | N/A |
| Revenue This Year | $3.49 | N/A |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | $72.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.78 | $4.25 |
| 52 Week High | $8.05 | $13.68 |
| Indicator | BBCP | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 42.62 |
| Support Level | $5.89 | $5.24 |
| Resistance Level | $6.32 | $6.11 |
| Average True Range (ATR) | 0.25 | 0.32 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 94.77 | 13.04 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators position it to deliver concrete placement solutions. The company's operating segment includes U.S. Concrete Pumping; U.K. Operations; U.S. Concrete Waste Management Services and Corporate. It generates maximum revenue from the U.S. Concrete Pumping segment. Geographically, it generates majority of the revenue from its business in United States.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.